| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 37.8 | 26.1 |
| Profit before tax | 19.7 | -1.0 |
| Net income | 19.2 | -0.5 |
| EPS (diluted, $ a share) | $0.26 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +44.8% |
|---|---|
| Operating margin | 30.6% |
10-Q filed with the SEC, NASDAQ: ZVRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zevra Therapeutics, Inc.: key numbers
- Share price
- $9.25Close, Nov 16
- Market cap
- $550M
- Shares outstanding
- 59.5MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zevra Therapeutics, Inc.
All →Zevra Therapeutics Financial Results
Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, a 45% increase year-over-year, primarily driven by $34.0 million in sales from MIPLYFFA. The company achieved net income of $19.2 million for the quarter and maintained a strong cash position of $270.9 million to support its rare disease pipeline.
- Term
- Q3 2026
“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease.”
Neil F. McFarlane, Zevra's President and Chief Executive Officer
“We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol. Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”
Neil F. McFarlane, Zevra's President and Chief Executive Officer
Zevra Therapeutics President and CEO Neil F. McFarlane Sells $225K of Stock
Neil F. McFarlane, President and CEO, sold 20,000 shares of Zevra Therapeutics, Inc. at $11.25 a share, worth $225K in total on Oct 12, 2026. Shares held after the trade: 417,225 (-4.6%).
- Value
- $225K
- Shares
- 20,000
- Price
- $11.25
- Role
- President and CEO
- Holding change
- -4.6%
- Trade date
- Oct 12, 2026